FY2024 EPS Estimates for AC Immune Boosted by HC Wainwright

AC Immune SA (NASDAQ:ACIU - Free Report) - Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for AC Immune in a report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.62) per share for the year, up from their prior estimate of ($0.91). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for AC Immune's Q4 2024 earnings at ($0.23) EPS, FY2025 earnings at $0.41 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.36 EPS and FY2028 earnings at $1.95 EPS.

Separately, StockNews.com downgraded shares of AC Immune from a "buy" rating to a "hold" rating in a report on Tuesday, October 1st.

AC Immune Stock Performance

Shares of NASDAQ ACIU traded down $0.07 during midday trading on Friday, reaching $3.20. The stock had a trading volume of 74,226 shares, compared to its average volume of 346,172. The company has a market capitalization of $316.61 million, a price-to-earnings ratio of -4.44 and a beta of 1.28. AC Immune has a 12-month low of $2.25 and a 12-month high of $5.14. The stock has a 50-day moving average of $3.27 and a 200-day moving average of $3.45.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($0.67). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Redmile Group LLC boosted its holdings in AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company's stock worth $5,941,000 after buying an additional 7,031 shares during the period. Renaissance Technologies LLC boosted its holdings in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company's stock worth $2,602,000 after buying an additional 136,300 shares during the period. Assenagon Asset Management S.A. boosted its holdings in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company's stock worth $1,755,000 after buying an additional 328,312 shares during the period. Cubist Systematic Strategies LLC bought a new position in AC Immune in the 2nd quarter worth $218,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock worth $72,000 after purchasing an additional 7,400 shares in the last quarter. Institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.